Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-241027 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1: BMS-241027 (0.003 mg/kg) | EXPERIMENTAL | - |
| Arm 2: BMS-241027 (0.01 mg/kg) | EXPERIMENTAL | - |
| Arm 3: BMS-241027 (0.03 mg/kg) | EXPERIMENTAL | - |
| Arm 4: Placebo matching BMS-241027 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-241027 | DRUG | Intravenous (IV), 0.003 mg/kg, Once Weekly, 9 weeks |
| Placebo matching BMS-241027 | DRUG | Intravenous (IV), 0.0 mg/kg, Once Weekly, 9 weeks |
Inclusion Criteria: * Mild AD Subjects meeting National Institute of Neurological Disorders and Stroke - Alzheimer's Disease Related Disorders Association(NINCDS-ADRDA) and Diagnostic and Statistical Manual of Mental Disorders-Forth Edition, Text Revision (DSM-IV-TR) criteria * Mini-Mental State Ex...
Top 20 of 24 competitors
BMS-241027 is an investigational small molecule being studied for the treatment of Alzheimer's Disease. It is intended for patients with mild Alzheimer's Disease, as evaluated in a clinical trial assessing its safety, tolerability, and effects on cerebrospinal fluid biomarkers. The drug is not approved and remains in clinical development.
The molecular target of BMS-241027 has not been disclosed in available information. The drug is a small molecule being investigated for its effects on cerebrospinal fluid biomarkers in patients with mild Alzheimer's Disease, but its specific mechanism of action is not publicly detailed.
BMS-241027 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The company sponsored a Phase 1 clinical trial of the drug in patients with mild Alzheimer's Disease.
BMS-241027 is in Phase 1 clinical development. A Phase 1 trial evaluating the drug has been completed, but the drug remains investigational and has not received regulatory approval. Its safety and efficacy are still being studied in clinical trials.
BMS-241027 has one completed clinical trial, identified as NCT01492374, titled "Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease." The trial enrolled 40 participants across the United States, Canada, France, Germany, and Sweden.